SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Difficult question concept. Big question mark or big problem to solve or finding solution, doubt or uncertainty, thinking to make decision, businessman holds up big question mark.
Drug pricing
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
At the heart of the agreement is Pfizer’s $70 billion commitment to U.S.-based manufacturing and an exemption from tariffs for three years. While the reaction was mostly positive from Wall Street, other observers noted that the benefits for patients are unclear at best.
October 1, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Fortress, Sentynl Fail To Secure FDA Nod in Rare Pediatric Disease
As with recent rejections for Biogen and Scholar Rock, manufacturing issues stymied a regulatory bid from Fortress Biotech and Sentynl Therapeutics. Fortress said the FDA did not flag problems with the drug’s safety or efficacy.
October 1, 2025
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol building
Government
US Government Shuts Down, FDA Closed for New Applications
Due to policies regarding industry user fees, the FDA will not be able to accept any new drug applications for the duration of the government shutdown, according to Leerink Partners.
October 1, 2025
 · 
4 min read
 · 
Annalee Armstrong
Receiving dividends among investors. Art collage.
Cancer
AnaptysBio Plans Business Split To Sharpen Focus on Asset Value
The business separation, expected to be completed by the end of 2026, will result in two new companies, one focused on biopharma operations and the other on royalty management.
October 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Marburg, Germany - July 6, 2013: Marburg Office of Swiss multinational company Novartis AG
Approvals
Novartis Secures First FDA Approval of Oral BTK Inhibitor for Chronic Hives
The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment.
October 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Sign of divorce. Broken paper heart on blue background, top view, copy space
Business
Novo Breaks $598M Heartseed Pact Amid ‘Decisive Restructuring’ by New CEO
Novo Nordisk and Heartseed first partnered in 2021 to develop an investigational cell therapy for heart failure.
October 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
M&A headlined for a second straight week as Genmab acquired Merus for $8 billion; Pfizer strikes most-favored-nation deal with White House; CDER Director George Tidmarsh caused a stir with a now-deleted LinkedIn post; GSK CEO Emma Walmsley will step down from her role; and uniQure’s gene therapy offers new hope for patients with Huntington’s disease.
October 1, 2025
 · 
2 min read
 · 
Heather McKenzie
Creative collage picture 3d hands body fragment banknote benjamin franklin hundred dollars deal agreement partnership business stats.
Mergers & acquisitions
Q3 Saw Some of the Highest-Value Biopharma Acquisitions of the Year So Far
J&J still holds the top deal of the year by value with its $14.6 billion buy of Intra-Cellular in January, but the next four biggest acquisitions came in the past four months.
October 1, 2025
 · 
2 min read
 · 
Annalee Armstrong
Trend artwork sketch montage 3D collage of young man hold laptop climb up pile coins economy savings cash trade finance career promotion.
Mergers & acquisitions
The Top Big Pharmas Have $1.2T in Stretch M&A Firepower Available
The two most historically deal-conservative Big Pharmas have the most money to play with for a major M&A transaction, according to a recent Stifel analysis.
October 1, 2025
 · 
6 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS